SHEILA SETTLEMIRES: Open Payments
NPI 1033531942 · CORINTH, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$405 in 22 payments from 9 companies in 2025. Trend: 2023 $148 · 2024 $95 · 2025 $405
Food & beverage: $405
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $100 |
| ABBVIE INC. | 3 | $52 |
| Novo Nordisk Inc | 3 | $46 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $39 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Lilly USA, LLC | 2 | $35 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| Amgen Inc. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $30 |
Products named: AIRSUPRA, Kerendia, FARXIGA, VRAYLAR, NEXLETOL, TRELEGY ELLIPTA, CAPLYTA, Rybelsus.
Industry payments across MS — which companies pay providers there.
